IL12B interleukin 12B
ENSG00000113302 · protein coding · Open Targets profile
Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, Med-Quality Pocket
- Antibody
- Approved Drug, GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
gnomAD loss of function constraint: o/e 0.6880999803543091 (upper bound 0.9489200115203857). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 180 registry trials, updated in the last three years, of the most advanced drugs against IL12B (briakinumab, guselkumab, mirikizumab, tildrakizumab, risankizumab, ebdarokimab, brazikumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Jo LambertUniversity Hospital, Ghent · 4 of 4 trials Phase 2+
- Kathy BohannonAstraZeneca · 4 of 4 trials Phase 2+
- Raymond ChoUniversity of California, San Francisco · 4 of 4 trials Phase 2+
- Alex G Ortega-LoayzaOregon Health and Science University, Department of Dermatology · 1 of 1 trials Phase 2+
- Alexis Ogdie-BeattyUniversity of Pennsylvania · 1 of 1 trials Phase 2+
- Anthony BUISSONUniversity Hospital, Clermont-Ferrand · 1 of 1 trials Phase 2+
- Benjamin D EhstOregon Medical Research Center · 1 of 1 trials Phase 2+
- Carlos G WambierDepartment of Dermatology, Warren Alpert Medical School of Brown University · 1 of 1 trials Phase 2+
- Casey ChapmanGIA · 1 of 1 trials Phase 2+
- Edward BarnesUniversity of North Carolina · 1 of 1 trials Phase 2+
- Elke de JongRadboud University Medical Center · 1 of 1 trials Phase 2+
- Guillaume LE COSQUERCHU de Toulouse- Hôpital Rangueil · 1 of 1 trials Phase 2+
- Johann De BonoNational Health Service, United Kingdom · 1 of 1 trials Phase 2+
- Jonathan SamuelsNYU Langone Health · 1 of 1 trials Phase 2+
- Jose ScherNYU Langone Health · 1 of 1 trials Phase 2+
Registry trials of briakinumab, guselkumab, mirikizumab, tildrakizumab, risankizumab, ebdarokimab, brazikumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 84 of 178 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 2 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
22 trials of drugs against IL12B were stopped early; 2 give no reason
Terminated, withdrawn and suspended interventional trials of briakinumab, guselkumab, mirikizumab, tildrakizumab, risankizumab, ebdarokimab, brazikumab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 22 most recent of 22.
- terminated · 2026-06-23 · AstraZeneca · Brazikumab low dose, Brazikumab high dose“Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.”
- terminated · 2026-06-23 · AstraZeneca · Brazikumab“Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.”
- terminated · 2026-06-23 · AstraZeneca · Brazikumab Maintenance Dose, Brazikumab Induction Dose“Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.”
- terminated · 2026-04-01 · AstraZeneca · Brazikumab Induction Dose, Brazikumab Maintenance Dose“Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.”
- terminated · 2025-07-01 · Janssen Research & Development, LLC · Guselkumab“The study primary endpoint was not met”
- terminated · 2025-06-15 · Centre for Human Drug Research, Netherlands · Guselkumab“Early termination was initiated as the recruitment of the remaining 14 moderate-to-severe patients stagnated.”
- terminated · 2025-04-29 · Janssen Research & Development, LLC · Guselkumab“Janssen made an internal business decision to discontinue the PROGRESS study. This decision is not related to any efficacy or safety concerns.”
- terminated · 2025-03-30 · Janssen-Cilag Ltd. · Guselkumab“Terminated (A strategic decision was made not to further execute the study. This decision was not based on a safety concern)”
- terminated · 2025-03-30 · Janssen Research & Development, LLC · Guselkumab Dose 1, Guselkumab Dose 2“Due to enrollment challenges, J\&J Innovative Medicine decided to stop screening and terminate the study early. This decision was not based on a safety concern.”
- terminated · 2025-03-14 · LEO Pharma · Guselkumab“The recruitment was terminated early due to delays and slow recruitment that significantly jeopardized the trial timelines. There were no safety concerns related to the early termination of the trial.”
- withdrawn · 2025-02-03 · Janssen Research & Development, LLC · Guselkumab“Study terminated. Sponsor decision.”
- terminated · 2024-04-25 · Institute of Cancer Research, United Kingdom · Tildrakizumab“Funder decided that response outcomes to date did not support continuation of the study.”
- terminated · 2023-03-21 · Eli Lilly and Company · Mirikizumab“The study was terminated due to a strategic business decision made by the Sponsor.”
- terminated · 2022-07-26 · Janssen Research & Development, LLC · Guselkumab, Risankizumab“The study was stopped due to unanticipated feasibility constraints.”
- withdrawn · 2022-02-24 · Sun Pharmaceutical Industries Limited · matched by the registry's drug synonymsNo reason given
- terminated · 2021-12-08 · Almirall, S.A. · Tildrakizumab“Low Recruitment”
- terminated · 2021-11-01 · Sun Pharmaceutical Industries Limited · matched by the registry's drug synonyms“Study terminated-Sponsor's decision”
- terminated · 2021-05-26 · AstraZeneca · Brazikumab IV Infusion, Brazikumab SC Injection“Study was terminated for business reasons; not due to safety or efficacy concerns.”
- withdrawn · 2021-05-06 · Eli Lilly and Company · Mirikizumab IV, Mirikizumab SC“The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.”
- withdrawn · 2020-06-05 · Rockefeller University · Guselkumab“COVID-19 Pandemic”
- withdrawn · 2011-10-21 · Abbott · briakinumab“Study stopped”
- terminated · 2011-08-23 · Abbott · matched by the registry's drug synonymsNo reason given
Paediatric incentives and obligations for IL12B's drugs
For briakinumab, guselkumab, mirikizumab, tildrakizumab, risankizumab, ebdarokimab, brazikumab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · IL12B is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000249046 (Guselkumab, Treatment of Crohn's disease): PM: decision on the application for modification of an agreed PIP, 10 Jul 2025; EMEA-001776-PIP01-15-M01 (risankizumab, Treatment of psoriasis): PM: decision on the application for modification of an agreed PIP, 2 Dec 2022; compliance positive 12 Sept 2025; EMA/PE/0000232930 (mirikizumab, Treatment of ulcerative colitis): PM: decision on the application for modification of an agreed PIP, 28 Jan 2025; EMA/PE/0000232848 (mirikizumab, Treatment of Crohn's disease): PM: decision on the application for modification of an agreed PIP, 28 Jan 2025; +11 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names briakinumab, guselkumab, mirikizumab, tildrakizumab, risankizumab, ebdarokimab, brazikumabRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Omvoh: authorised since 26 May 2023; Skyrizi: authorised since 26 Apr 2019; Ilumetri: authorised since 17 Sept 2018; Tremfya: authorised since 10 Nov 2017; +1 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of briakinumab, guselkumab, mirikizumab, tildrakizumab, risankizumab, ebdarokimab, brazikumabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 27 interventional studies of briakinumab, guselkumab, mirikizumab, tildrakizumab, risankizumab, ebdarokimab, brazikumab include patients under 18; 16 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 8 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.